| ［1］ |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17–48.
|
| ［2］ |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394–424.
|
| ［3］ |
Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(1): 7–24.
|
| ［4］ |
Aznar MA, Good CR, Barber-Rotenberg JS, et al. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer[J]. Cell Rep Med, 2025, 6(9): 102301.
|
| ［5］ |
Wang J, Zhang T, Li P, et al. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC[J]. Cancer Lett, 2023, 573: 216366.
|
| ［6］ |
Ling X, Wu W, Aljahdali IAM, et al. FL118, acting as a ‘molecular glue degrader’, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy[J]. Clin Transl Med, 2022, 12(5): e881.
|
| ［7］ |
Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618(7963): 144–150.
|
| ［8］ |
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592): 47–52.
|
| ［9］ |
Pei G, Min J, Rajapakshe KI, et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer[J]. Nature, 2025, 642(8066): 212–221.
|
| ［10］ |
Iovanna J, Fraunhoffer N, Urrutia R, et al. Understanding the heterogeneity of pancreatic ductal adenocarcinoma[J]. Transl Oncol, 2025, 60: 102479.
|
| ［11］ |
Noë M, Hong SM, Wood LD, et al. Pancreatic cancer pathology viewed in the light of evolution[J]. Cancer Metastasis Rev, 2021, 40(3): 661–674.
|
| ［12］ |
Seth S, Li CY, Ho IL, et al. Pre-existing functional heterogeneity of tumorigenic compartment as the origin of chemoresistance in pancreatic tumors[J]. Cell Rep, 2019, 26(6): 1518–1532, e9.
|
| ［13］ |
Tabassum DP, Polyak K. Tumorigenesis: it takes a village[J]. Nat Rev Cancer, 2015, 15(8): 473–483.
|
| ［14］ |
Grünwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer[J]. Cell, 2021, 184(22): 5577–5592, e18.
|
| ［15］ |
Shakiba M, Tuveson DA. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer[J]. Nat Immunol, 2025, 26(5): 678–691.
|
| ［16］ |
Li M, Freeman S, Franco-Barraza J, et al. A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism[J]. Biomaterials, 2024, 310: 122631.
|
| ［17］ |
Xie W, Yu X, Yang Q, et al. The immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer[J]. Cancer Discov, 2025, 15(8): 1740–1765.
|
| ［18］ |
Jia W, Wang J, Yang W, et al. Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma[J]. J Immunother Cancer, 2025, 13(10): e012314.
|
| ［19］ |
Naba A. Mechanisms of assembly and remodelling of the extracellular matrix[J]. Nat Rev Mol Cell Biol, 2024, 25(11): 865–885.
|
| ［20］ |
Jin R, Neufeld L, McGaha TL. Linking macrophage metabolism to function in the tumor microenvironment[J]. Nat Cancer, 2025, 6(2): 239–252.
|
| ［21］ |
Zhang T, Yu W, Cheng X, et al. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity[J]. Sci Immunol, 2024, 9(94): eadh2334.
|
| ［22］ |
Peralta RM, Xie B, Lontos K, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism[J]. Nat Immunol, 2024, 25(12): 2297–2307.
|
| ［23］ |
Ding J, Xie Y, Liu Z, et al. Hypoxic and acidic tumor microenvironment-driven AVL9 promotes chemoresistance of pancreatic ductal adenocarcinoma via the AVL9-IκBα-SKP1 complex[J]. Gastroenterology, 2025, 168(3): 539–555, e5.
|
| ［24］ |
Wu W, Wen K, Zhong Y. Research progress in the establishment of pancreatic cancer models and preclinical applications[J]. Cancer Innov, 2022, 1(3): 207–219.
|
| ［25］ |
Gopinathan A, Morton JP, Jodrell DI, et al. GEMMs as preclinical models for testing pancreatic cancer therapies[J]. Dis Model Mech, 2015, 8(10): 1185–200.
|
| ［26］ |
Ju Y, Xu D, Liao MM, et al. Barriers and opportunities in pancreatic cancer immunotherapy[J]. NPJ Precis Oncol, 2024, 8(1): 199.
|
| ［27］ |
Liu Y, Wu W, Cai C, et al. Patient-derived xenograft models in cancer therapy: technologies and applications[J]. Signal Transduct Target Ther, 2023, 8(1): 160.
|
| ［28］ |
Blanchard Z, Brown EA, Ghazaryan A, et al. PDX models for functional precision oncology and discovery science[J]. Nat Rev Cancer, 2025, 25(3): 153–166.
|
| ［29］ |
Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine[J]. Nat Rev Mol Cell Biol, 2020, 21(10): 571–584.
|
| ［30］ |
Rüland L, Andreatta F, Massalini S, et al. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss[J]. Nat Commun, 2023, 14(1): 2377.
|
| ［31］ |
Hu W, Lazar MA. Modelling metabolic diseases and drug response using stem cells and organoids[J]. Nat Rev Endocrinol, 2022, 18(12): 744–759.
|
| ［32］ |
Corsini NS, Knoblich JA. Human organoids: new strategies and methods for analyzing human development and disease[J]. Cell, 2022, 185(15): 2756–2769.
|
| ［33］ |
Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer[J]. Lancet, 2025, 405(10485): 1182–1202.
|
| ［34］ |
Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5): 752–765.
|
| ［35］ |
Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer[J]. Diabetes, 2017, 66(5): 1103–1110.
|
| ［36］ |
Yang J, Xu R, Wang C, et al. Early screening and diagnosis strategies of pancreatic cancer: A comprehensive review[J]. Cancer Commun (Lond), 2021, 41(12): 1257–1274.
|
| ［37］ |
曹喆, 翁桂湖, 刘涛, 等. 新型预后营养炎症评分系统建立以有效预测胰腺癌根治术后患者的长期预后[J/OL]. 中华普通外科学文献（电子版）, 2026, 20(2): 85-90.
|
| ［38］ |
Montoya Mira JL, Quentel A, Patel RK, et al. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay[J]. Sci Transl Med, 2025, 17(785): eadq3110.
|
| ［39］ |
沈珊珊, 李洪祯, 余媛媛. 中国胰腺癌高危人群早期筛查和监测共识意见(2021, 南京)[J]. 临床肝胆病杂志, 2022, 38(5): 1016–1022.
|
| ［40］ |
du Toit-Thompson T, Leck L, Gillson J, et al. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies[J]. Adv Drug Deliv Rev, 2025, 224: 115647.
|
| ［41］ |
中华医学会肿瘤学分会早诊早治学组. 中华医学会肿瘤学分会胰腺癌早诊早治专家共识[J]. 中华肿瘤杂志, 2020, 42(9): 706–712.
|
| ［42］ |
Pinelli D, Micalef A, Merelli B, et al. Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: surgical results in a small series[J]. Cancer Treat Res Commun, 2023, 37: 100770.
|
| ［43］ |
Lowery MA, Kelsen DP, Capanu M, et al. Phase Ⅱ trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma[J]. Eur J Cancer, 2018, 89: 19–26.
|
| ［44］ |
Yan L, Raj P, Yao W, et al. Glucose metabolism in pancreatic cancer[J]. Cancers (Basel), 2019, 11(10): 1460.
|
| ［45］ |
Li Y, Tang S, Wang H, et al. A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy[J]. Cell Stem Cell, 2025, 32(9): 1369–1389, e14.
|
| ［46］ |
Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach[J]. Ann Oncol, 2019, 30(8): 1232–1243.
|
| ［47］ |
Wu ST, Zhu L, Feng XL, et al. Advances in neoadjuvant therapy for pancreatic cancer: current trends and future directions[J]. World J Clin Oncol, 2025, 16(6): 105849.
|
| ［48］ |
Konno H, Yamauchi S, Berglund A, et al. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production[J]. Oncogene, 2018, 37(15): 2037–2051.
|
| ［49］ |
Mao C, Fan W, Liu J, et al. Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-deficient tumor[J]. Adv Sci (Weinh), 2025, 12(41): e07904.
|
| ［50］ |
陈健聪, 赖佳明. 胰腺癌系统治疗2024年度研究进展[J/CD]. 消化肿瘤杂志（电子版）, 2025, 17(1): 23-26.
|
| ［51］ |
Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Author correction: transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution[J]. Nat Genet, 2020, 52(4): 463.
|
| ［52］ |
Okamura Y, Yasukawa S, Narimatsu H, et al. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy[J]. Cancer Sci, 2020, 111(2): 548–560.
|
| ［53］ |
Zhu Y, Qi M, Lao L, et al. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: A meta-analysis[J]. Genet Test Mol Biomarkers, 2014, 18(5): 306–312.
|
| ［54］ |
Peng C, Oberstein PE. Emerging therapeutic approaches to pancreatic adenocarcinoma: advances and future directions[J]. Curr Treat Options Oncol, 2025, 26(10): 841–865.
|
| ［55］ |
Quinn PL, McAlearney AS, Eramo J, et al. Factors impacting informed decision-making for patients with pancreatic cancer: A qualitative study[J]. Support Care Cancer, 2025, 33(9): 825.
|
| ［56］ |
Sarno F, Tenorio J, Perea S, et al. A Phase Ⅲ randomized trial of integrated genomics and avatar models for personalized treatment of pancreatic cancer: the AVATAR trial[J]. Clin Cancer Res, 2025, 31(2): 278–287.
|
| ［57］ |
Cobianchi L, Dal Mas F, Pizzocaro E, et al. Co-design, co-learning, and co-production of an App for pancreatic cancer patients-the “Pancreas Plus” study protocol[J]. Mhealth, 2023, 9: 16.
|